Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Lu-Ting Kuo
 + 1011 word(s) 1011 2021-05-20 12:43:48 |
2 format correct
Lindsay Dong
Meta information modification 1011 2021-05-23 15:02:15 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Kuo, L. Hydrocephalus Following Aneurysmal Subarachnoid Hemorrhage. Encyclopedia. Available online: https://encyclopedia.pub/entry/9969 (accessed on 23 April 2024).
Kuo L. Hydrocephalus Following Aneurysmal Subarachnoid Hemorrhage. Encyclopedia. Available at: https://encyclopedia.pub/entry/9969. Accessed April 23, 2024.
Kuo, Lu-Ting. "Hydrocephalus Following Aneurysmal Subarachnoid Hemorrhage" Encyclopedia, https://encyclopedia.pub/entry/9969 (accessed April 23, 2024).
Kuo, L. (2021, May 23). Hydrocephalus Following Aneurysmal Subarachnoid Hemorrhage. In Encyclopedia. https://encyclopedia.pub/entry/9969
Kuo, Lu-Ting. "Hydrocephalus Following Aneurysmal Subarachnoid Hemorrhage." Encyclopedia. Web. 23 May, 2021.
Hydrocephalus Following Aneurysmal Subarachnoid Hemorrhage
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms22095050

Hydrocephalus is a common complication of aneurysmal subarachnoid hemorrhage (aSAH) and reportedly contributes to poor neurological outcomes.

cerebral aneurysm subarachnoid hemorrhage hydrocephalus shunt pathogenesis inflammation

1. Introduction

Aneurysmal subarachnoid hemorrhage (aSAH) remains a devastating disease that is characterized by a high mortality rate and significant morbidity amongst survivors [1][2]. Hydrocephalus is a frequently encountered complication following aSAH and is classified as acute (0–3 days post-SAH), subacute (4–13 days post-SAH), or chronic (14 days post-SAH) [3][4]. Acute hydrocephalus necessitates the placement of an external ventricular drain (EVD) to reduce deleterious secondary effects after the aneurysm bleed, with up to 48% of EVD recipients requiring ventriculoperitoneal (VP) shunt insertion [5][6][7].

Various mechanisms have been implicated as causative factors for the development of chronic hydrocephalus following aSAH, including alterations in CSF dynamics, obstruction of the arachnoid granulations by blood products, and adhesions within the ventricular system [8][9][10].

Chronic hydrocephalus following aSAH reportedly contributes to poor neurological outcomes and severe cognitive deficits [11][12][13][14] (Figure 1). The development of predictive models that could stratify patients with aSAH based on their risk of developing shunt-dependent chronic hydrocephalus is important.

Ijms 22 05050 g001 550

Figure 1. The series of computed tomography (CT) images of a case with aSAH. (A) A 68 years-old female patient presented with SAH at admission. There is no IVH and no acute hydrocephalus; (B) a ruptured left posterior communicating artery aneurysm was identified and coiled; (C) on 12 days after aSAH, CT showed hydrocephalus. She developed progressive ataxia and cognitive dysfunction.

Following aSAH, evidence suggests that extensive fibrosis in the subarachnoid space may be an important cause of chronic hydrocephalus development [8][15].

2. Transforming Growth Factor (TGF) and Its Antagonists

TGF-β1 levels have been reported to be higher in the CSF following aSAH, especially in patients with hydrocephalus, which implies its role in the pathogenesis of subarachnoid fibrosis and chronic hydrocephalus following aSAH [16][17][18]. Some TGF-β1 antagonists and TGF-β1 signaling pathway inhibitors alleviate chronic hydrocephalus and improve behavioral outcomes in rat aSAH models [19][20]. 

3. Tenascin-C

TNC may cause leptomeningeal collagen synthesis and fibrosis, as well as brain injuries with decreased brain parenchymal volume contributing to subsequent ventricular enlargement, resulting in the development of chronic hydrocephalus, which is consistent with findings from a CSF study in humans [21][22].

4. SIRS Following aSAH

SAH causes a systemic inflammatory response syndrome (SIRS) that involves complex interactions amongst immune cells, inflammation, coagulation, sympathoadrenal activation, endothelial cell activation, and dysfunction [23]. This complex process leads to a procoagulant reaction, tissue hypoperfusion, microthrombosis, and compromised microcirculation, which ultimately leads to multiorgan failure [23][24][25]. Release of catecholamines into the systemic circulation following aSAH may cause arrhythmias and neurogenic pulmonary edema.

5. Immune Dysregulation Following aSAH

The immune response following aSAH has been described in recent publications. Following aSAH, systemic IL-6 levels increase rapidly, whereas IL-10 levels are reduced [26]. Neutrophils are increased both in the brain and in the blood, reflecting local and peripheral inflammation following aSAH [27]. Higher levels of intracerebral proinflammatory monocytes are found within 24 h than after 1 week [26]. In addition to stroke-related SIRS, immune dysregulation plays an important role in brain injury and recovery. For example, the spleen contracts following ischemic stroke, activating a peripheral immune response that may exacerbate ongoing brain injury [28]. 

6. Inflammation-Dependent Hypersecretion of CSF Following aSAH

The rate of shunt dependency after treated aSAH ranges from 17.2% to 31.2% [14][29]. The four mechanisms underlying the pathophysiology of aSAH-induced brain injury are acute obstructive hydrocephalus, a mass effect exerted by IVH, SAH-related cytotoxic blood degradation products in the adjacent brain tissue, and chronic hydrocephalus [30] (Figure 2). Acute hydrocephalus requires EVD management, while using EVD may also cause chronic hydrocephalus. When chronic hydrocephalus progresses, EVD cannot be removed and may need a permanent shunt. The clearance of blood clots from the ventricles has therefore become a major therapeutic goal.

Ijms 22 05050 g002 550

Figure 2. Surgeries applied for four mechanisms underlying the pathophysiology of aSAH-induced brain injury.

7. Endoscopic IVH Removal

Endoscopic IVH removal can be useful in certain cases. Although the published series on endoscopic IVH removal detail results similar to those with IVF, no randomized trial has proven the superiority of this approach over EVD + IVF or EVD alone. Although the combination of coiling and endoscopic IVH removal in aSAH patients has proven safe and effective, given the technical demand of endoscopic IVH removal, evidence demonstrating its superiority over EVD + IVF is needed before it can be widely adopted [31][32][33][34]. This can be performed in the hybrid room with a multidisciplinary team with coiling performed before or after endoscopic IVH removal [33][34]. The hybrid operating room enables the two treatment approaches to be performed without the need to transfer the patient, and thereby minimizes the transition time between the modalities.

8. Coil vs. Clip and Their Relationship with Shunt Dependency

Although the influence of treatment modality (surgical clipping versus endovascular coiling) on shunt dependency remains controversial, it has been postulated that open surgery allows irrigation and removal of subarachnoid clots and thereby reduces the probability of chronic hydrocephalus [35][36]. Some studies have suggested that endovascular treatment is independently associated with the development of chronic hydrocephalus in aSAH patients [36][37]. However, other research has demonstrated a significantly lower incidence of chronic hydrocephalus after endovascular treatment compared with after surgical clipping [38].

Some surgical techniques have been shown to decrease the risk of shunt dependency. Tandem fenestration of the lamina terminalis and membrane of Liliequist has been shown to decrease shunt dependency following surgical clipping or bypass following aSAH (17.9% vs. 3.2%) [39].

9. Summary

To sum up, the development of shunt-dependent hydrocephalus following aSAH is multifactorial. The involvement of multiple cellular signaling pathways and inflammatory responses all contribute to its pathogenesis. This review integrates the updated knowledge about the clinical, molecular, prognostic, and therapeutic aspects of chronic hydrocephalus following aSAH. Recent literature has shown that prolonged use of EVD in the acute stage may lead to subsequent hydrocephalus. There is a need to standardize the EVD weaning process to decrease shunt dependency. Although lumbar drainage and IVF may decrease shunt dependency, those still need further validation. There have been no ideal treatment approaches for this devastating disease which points to a need for therapeutic strategies to target these underlying mechanisms. Understanding the risk factors and molecular pathophysiology related to the development of hydrocephalus following aSAH may help neurosurgeons to determine the intervention targeting these factors.

References

  1. Van Gijn, J.; Rinkel, G.J. Subarachnoid haemorrhage: Diagnosis, causes and management. Brain A J. Neurol. 2001, 124, 249–278.
  2. Van Gijn, J.; Kerr, R.S.; Rinkel, G.J. Subarachnoid haemorrhage. Lancet 2007, 369, 306–318.
  3. Vale, F.L.; Bradley, E.L.; Fisher, W.S., 3rd. The relationship of subarachnoid hemorrhage and the need for postoperative shunting. J. Neurosurg. 1997, 86, 462–466.
  4. Kwon, J.H.; Sung, S.K.; Song, Y.J.; Choi, H.J.; Huh, J.T.; Kim, H.D. Predisposing factors related to shunt-dependent chronic hydrocephalus after aneurysmal subarachnoid hemorrhage. J. Korean Neurosurg. Soc. 2008, 43, 177–181.
  5. O’Kelly, C.J.; Kulkarni, A.V.; Austin, P.C.; Urbach, D.; Wallace, M.C. Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage: Incidence, predictors, and revision rates. Clinical article. J. Neurosurg. 2009, 111, 1029–1035.
  6. Bederson, J.B.; Connolly, E.S., Jr.; Batjer, H.H.; Dacey, R.G.; Dion, J.E.; Diringer, M.N.; Duldner, J.E., Jr.; Harbaugh, R.E.; Patel, A.B.; Rosenwasser, R.H. Guidelines for the management of aneurysmal subarachnoid hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009, 40, 994–1025.
  7. Quigley, M. Risk of shunt-dependent hydrocephalus after occlusion of ruptured intracranial aneurysms by surgical clipping or endovascular coiling: A single-institution series and meta-analysis. Neurosurgery 2008, 63, E1209.
  8. Dóczi, T.; Nemessányi, Z.; Szegváry, Z.; Huszka, E. Disturbances of cerebrospinal fluid circulation during the acute stage of subarachnoid hemorrhage. Neurosurgery 1983, 12, 435–438.
  9. Wilson, C.D.; Safavi-Abbasi, S.; Sun, H.; Kalani, M.Y.; Zhao, Y.D.; Levitt, M.R.; Hanel, R.A.; Sauvageau, E.; Mapstone, T.B.; Albuquerque, F.C.; et al. Meta-analysis and systematic review of risk factors for shunt dependency after aneurysmal subarachnoid hemorrhage. J. Neurosurg. 2017, 126, 586–595.
  10. Czorlich, P.; Ricklefs, F.; Reitz, M.; Vettorazzi, E.; Abboud, T.; Regelsberger, J.; Westphal, M.; Schmidt, N.O. Impact of intraventricular hemorrhage measured by Graeb and LeRoux score on case fatality risk and chronic hydrocephalus in aneurysmal subarachnoid hemorrhage. Acta Neurochir. 2015, 157, 409–415.
  11. Paisan, G.M.; Ding, D.; Starke, R.M.; Crowley, R.W.; Liu, K.C. Shunt-Dependent Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage: Predictors and Long-Term Functional Outcomes. Neurosurgery 2018, 83, 393–402.
  12. Haug Nordenmark, T.; Karic, T.; Sorteberg, W.; Sorteberg, A. Predictors of cognitive function in the acute phase after aneurysmal subarachnoid hemorrhage. Acta Neurochir. 2019, 161, 177–184.
  13. Di Russo, P.; Di Carlo, D.T.; Lutenberg, A.; Morganti, R.; Evins, A.I.; Perrini, P. Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage. J. Neurosurg. Sci. 2020, 64, 181–189.
  14. Zaidi, H.A.; Montoure, A.; Elhadi, A.; Nakaji, P.; McDougall, C.G.; Albuquerque, F.C.; Spetzler, R.F.; Zabramski, J.M. Long-term functional outcomes and predictors of shunt-dependent hydrocephalus after treatment of ruptured intracranial aneurysms in the BRAT trial: Revisiting the clip vs coil debate. Neurosurgery 2015, 76, 608–613; discussion 604–613; quiz 614.
  15. Golanov, E.V.; Bovshik, E.I.; Wong, K.K.; Pautler, R.G.; Foster, C.H.; Federley, R.G.; Zhang, J.Y.; Mancuso, J.; Wong, S.T.; Britz, G.W. Subarachnoid hemorrhage—Induced block of cerebrospinal fluid flow: Role of brain coagulation factor III (tissue factor). J. Cereb. Blood Flow Metab. 2018, 38, 793–808.
  16. Liu, F.; Yuan, W.; Liao, D.; Zhang, T.; Wang, Z. Association of chronic hydrocephalus after aneurysmal subarachnoid hemorrhage with transforming growth factor-β1 levels and other risk factors. Nan Fang Yi Ke Da Xue Xue Bao = J. South. Med. Univ. 2013, 33, 382–385.
  17. Douglas, M.R.; Daniel, M.; Lagord, C.; Akinwunmi, J.; Jackowski, A.; Cooper, C.; Berry, M.; Logan, A. High CSF transforming growth factor beta levels after subarachnoid haemorrhage: Association with chronic communicating hydrocephalus. J. Neurol. Neurosurg. Psychiatry 2009, 80, 545–550.
  18. Kaestner, S.; Dimitriou, I. TGF beta1 and TGF beta2 and their role in posthemorrhagic hydrocephalus following SAH and IVH. J. Neurol. Surg. Part A Cent. Eur. Neurosurg. 2013, 74, 279–284.
  19. Dong, C.; Ming, X.; Ye, Z.; Wang, P.; Wang, L.; Li, Z.; Pan, B. Icariside II Attenuates Chronic Hydrocephalus in an Experimental Subarachnoid Hemorrhage Rat Model. J. Pharm. Pharm. Sci. 2018, 21, 318–325.
  20. Yan, H.; Chen, Y.; Li, L.; Jiang, J.; Wu, G.; Zuo, Y.; Zhang, J.H.; Feng, H.; Yan, X.; Liu, F. Decorin alleviated chronic hydrocephalus via inhibiting TGF-β1/Smad/CTGF pathway after subarachnoid hemorrhage in rats. Brain Res. 2016, 1630, 241–253.
  21. Suzuki, H.; Kinoshita, N.; Imanaka-Yoshida, K.; Yoshida, T.; Taki, W. Cerebrospinal fluid tenascin-C increases preceding the development of chronic shunt-dependent hydrocephalus after subarachnoid hemorrhage. Stroke 2008, 39, 1610–1612.
  22. Nakatsuka, Y.; Kawakita, F.; Yasuda, R.; Umeda, Y.; Toma, N.; Sakaida, H.; Suzuki, H. Preventive effects of cilostazol against the development of shunt-dependent hydrocephalus after subarachnoid hemorrhage. J. Neurosurg. 2017, 127, 319–326.
  23. de Oliveira Manoel, A.L.; Macdonald, R.L. Neuroinflammation as a Target for Intervention in Subarachnoid Hemorrhage. Front. Neurol. 2018, 9, 292.
  24. Ray, B.; Ross, S.R.; Danala, G.; Aghaei, F.; Nouh, C.D.; Ford, L.; Hollabaugh, K.M.; Karfonta, B.N.; Santucci, J.A.; Cornwell, B.O.; et al. Systemic response of coated-platelet and peripheral blood inflammatory cell indices after aneurysmal subarachnoid hemorrhage and long-term clinical outcome. J. Crit. Care 2019, 52, 1–9.
  25. Matsukura, S.; Sakamoto, N.; Imura, H.; Matsuyama, H.; Tamada, T.; Ishiguro, T.; Muranaka, H. Radioimmunoassay of nicotine. Biochem. Biophys. Res. Commun. 1975, 64, 574–580.
  26. Gris, T.; Laplante, P.; Thebault, P.; Cayrol, R.; Najjar, A.; Joannette-Pilon, B.; Brillant-Marquis, F.; Magro, E.; English, S.W.; Lapointe, R.; et al. Innate immunity activation in the early brain injury period following subarachnoid hemorrhage. J. Neuroinflamm. 2019, 16, 1–16.
  27. Chou, S.H.; Feske, S.K.; Simmons, S.L.; Konigsberg, R.G.; Orzell, S.C.; Marckmann, A.; Bourget, G.; Bauer, D.J.; De Jager, P.L.; Du, R.; et al. Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outcome following subarachnoid hemorrhage. Transl. Stroke Res. 2011, 2, 600–607.
  28. Vahidy, F.S.; Parsha, K.N.; Rahbar, M.H.; Lee, M.; Bui, T.T.; Nguyen, C.; Barreto, A.D.; Bambhroliya, A.B.; Sahota, P.; Yang, B.; et al. Acute splenic responses in patients with ischemic stroke and intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 2016, 36, 1012–1021.
  29. Jabbarli, R.; Bohrer, A.M.; Pierscianek, D.; Müller, D.; Wrede, K.H.; Dammann, P.; El Hindy, N.; Özkan, N.; Sure, U.; Müller, O. The CHESS score: A simple tool for early prediction of shunt dependency after aneurysmal subarachnoid hemorrhage. Eur. J. Neurol. 2016, 23, 912–918.
  30. Gaberel, T.; Magheru, C.; Emery, E. Management of non-traumatic intraventricular hemorrhage. Neurosurg. Rev. 2012, 35, 485–494; discussion 485–494.
  31. Iwaasa, M.; Ueba, T.; Nonaka, M.; Okawa, M.; Abe, H.; Higashi, T.; Inoue, T. Safety and feasibility of combined coiling and neuroendoscopy for better outcomes in the treatment of severe subarachnoid hemorrhage accompanied by massive intraventricular hemorrhage. J. Clin. Neurosci. 2013, 20, 1264–1268.
  32. Iwaasa, M.; Ueba, T.; Okawa, M.; Inoue, T. Analysis of combined coiling and neuroendoscopy in the treatment of intraventricular hemorrhage due to ruptured aneurysm. Acta Neurochir. Suppl. 2014, 119, 49–52.
  33. Longatti, P.; Fiorindi, A.; Di Paola, F.; Curtolo, S.; Basaldella, L.; Martinuzzi, A. Coiling and neuroendoscopy: A new perspective in the treatment of intraventricular haemorrhages due to bleeding aneurysms. J. Neurol. Neurosurg. Psychiatry 2006, 77, 1354–1358.
  34. Mori, R.; Yuki, I.; Kajiwara, I.; Nonaka, Y.; Ishibashi, T.; Karagiozov, K.; Dahmani, C.; Murayama, Y. Hybrid Operating Room for Combined Neuroendovascular and Endoscopic Treatment of Ruptured Cerebral Aneurysms with Intraventricular Hemorrhage. World Neurosurg. 2016, 89, 727.e9–727.e12.
  35. Xie, Z.; Hu, X.; Zan, X.; Lin, S.; Li, H.; You, C. Predictors of Shunt-dependent Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage? A Systematic Review and Meta-Analysis. World Neurosurg. 2017, 106, 844–860.e846.
  36. Varelas, P.; Helms, A.; Sinson, G.; Spanaki, M.; Hacein-Bey, L. Clipping or coiling of ruptured cerebral aneurysms and shunt-dependent hydrocephalus. Neurocrit. Care 2006, 4, 223–228.
  37. de Oliveira, J.G.; Beck, J.; Setzer, M.; Gerlach, R.; Vatter, H.; Seifert, V.; Raabe, A. Risk of shunt-dependent hydrocephalus after occlusion of ruptured intracranial aneurysms by surgical clipping or endovascular coiling: A single-institution series and meta-analysis. Neurosurgery 2007, 61, 924–933; discussion 924–934.
  38. Koyanagi, M.; Fukuda, H.; Saiki, M.; Tsuji, Y.; Lo, B.; Kawasaki, T.; Ioroi, Y.; Fukumitsu, R.; Ishibashi, R.; Oda, M.; et al. Effect of choice of treatment modality on the incidence of shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage. J. Neurosurg. 2018, 130, 949–955.
  39. Winkler, E.A.; Burkhardt, J.K.; Rutledge, W.C.; Rick, J.W.; Partow, C.P.; Yue, J.K.; Birk, H.; Bach, A.M.; Raygor, K.P.; Lawton, M.T. Reduction of shunt dependency rates following aneurysmal subarachnoid hemorrhage by tandem fenestration of the lamina terminalis and membrane of Liliequist during microsurgical aneurysm repair. J. Neurosurg. 2018, 129, 1166–1172.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Lu-Ting Kuo
View Times: 788
Revisions: 2 times (View History)
Update Date: 25 May 2021
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback